The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.
Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS.
Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)/Ethical Committee (EC) approval in accordance with national and local subject privacy regulations.
Patients under 18 years of age will be excluded.
Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.
icometrix
Lead sponsor
Charite University, Berlin, Germany
Collaborator
Ruhr University of Bochum
Collaborator
Technische Universität Dresden
Collaborator
University Hospital, Lille
Collaborator
Casa di Cura IGEA
Collaborator
General University Hospital, Prague
Collaborator
Hoffmann-La Roche
Collaborator
Bristol-Myers Squibb
Collaborator
Imcyse SA
Collaborator
AB Science
Collaborator
Nocturne UG
Collaborator
Aalto University
Collaborator